Apoptosis-inducing vanadocene compounds against human testicular cancer

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1536-1545

  Ghosh, Phalguni ^a,b   D'Cruz, Osmond J ^a,b   Narla, Rama Krishna ^a,b   Uckun, Fatih M ^a,b  

^a PARKER HUGHES INSTITUTE   (United States)

^b Parker Hughes Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HAFNIUM; MOLYBDENUM COMPLEX; SELENIUM DERIVATIVE; THIOCYANATE; TITANOCENE DICHLORIDE; VANADIUM DERIVATIVE; ZIRCONOCENE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TESTIS CANCER;

APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; MALE; ORGANOMETALLIC COMPOUNDS; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED; VANADIUM COMPOUNDS;

EID: 0034005632     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. O'Callaghan, A., and Mead, G. M. Testicular carcinoma. Postgrad. Med. J., 73: 481-486, 1997.
2. Bell, I. Testicular self examination. Nurs. Times, 86: 38-40, 1990.
3. Einhorn, L. H. Complicated problems in testicular cancer. Semin. Oncol., 15 (Suppl. 3): 9-15, 1988.
4. Lugagne-Delpon, P. M., Petit, M., Houlgatte, A., and Droz, J. P. Survival and quality of life of patients with testicular cancer. Ann. Urol. Paris, 32: 80-82, 1998.
5. Peterson, P. M., Hansen, S. W., Giwercman, A., Rorth, M., and Skakkebaek, N. E. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy of germ cell tumor. Ann. Oncol., 5: 355-358, 1994.
6. Drasga, R. E., Einhorn, L. H., Williams, S. D., Patel, D. N., and Stevens, E. E. Fertility after chemotherapy for testicular cancer. J. Clin. Oncol., 1: 179-183, 1983.
7. 2, M = Ti, V, Zr. Aqueous kinetics, equilibria, and mechanistic implications for a new class of antitumor agents. J. Am. Chem. Soc., 107; 947-953, 1985.
8. 2, with nucleotides and phosphoesters. Mechanistic implications for a new class of antitumor agents. J. Am. Chem. Soc., 108: 7263-7274, 1986.
9. Kopf-Maier, P., Wagner, W., Hasse, B., and Kopf, H. Tumor inhibition by metallocenes: activity against leukemias and detection of the systematic effect. Eur. J. Cancer, 77: 665-669, 1981.
10. Kopf-Maier, P., Wagner, W., and Kopf. H. In vitro cell growth inhibition by metallocene dichlorides. Cancer Chemother. Pharmacol., 5: 237-241, 1981.
11. Kopf-Maier, P., and Kopf, H. Non-platinum-group metal antitumor agents: history, current status, and perspectives. Chem. Rev., 87: 1137-1152, 1987.
12. Murthy, M. S., Rao, L. N., Kuo, L. Y., Toney, J. H., and Marks, T. J. Antitumor and toxicologic properties of the organometallic anticancer agent vanadocene dichloride. Inorg. Chimica Acta, 152: 117-124, 1988.
13. Djordjevic, C. Antitumor activity of vanadium compounds. In: H. Sigel and A. Sigel (eds.), Metal Ions in Biological Systems, Vol. 31, pp. 595-616. New York: Marcel Dekker, 1995.
14. 2-type complex. J. Am. Chem. Soc., 97: 6422-6433, 1975.
15. Kuo, Y. L., Liu, A. H., and Marks, T. J. Metallocene interactions with DNA and DNA-processing enzymes. In: H. Sigel and A. Sigel (eds.), Metal Ions in Biological Systems, Vol. 31, pp. 53-85. New York: Marcel Dekker, 1995.
16. Köpf-Maier, P., and Hermann, G. Cytologic observations on the effects of metallocene dichlorides on human fibroblasts cultivated in vitro. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol., 47: 107-122, 1984.
17. 2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. J. Cancer Res. Clin. Oncol., 106: 44-52, 1983.
18. Köpf-Maier, P., and Krahl, D. Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem.-Biol. Interact., 44: 317-328, 1983.
19. Köpf-Maier, P., and Kopf, H. Tumor inhibition by titanocene complexes: activity against B16 melanoma and colon 38 carcinoma. Arzneim. Forschung., 37: 532-534, 1987.
20. Köpf-Maier, P. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas. J. Cancer Res. Clin. Oncol., 113: 342-348, 1987.
21. Köpf-Maier, P., and Köpf, H. Transition and main-group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type. Struct. Bonding, 70: 103-185, 1988.
22. Moebus, V. J., Stein, R., Kieback, D. G., Runnebaum, I. B., Sass, G., and Kreienberg, R. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives. Anticancer Res., 17: 815-822, 1997.
23. Holloway, J. D. L., and Geiger, W. E., Jr. Electron-transfer reactions of metallocenes. Influence of metal oxidation state on structure and reactivity. J. Am. Chem. Soc., 101: 2038-2044, 1979.
24. Hirao, T. Vanadium in modern organic synthesis. Chem. Rev., 97: 2707-2724, 1997.
25. Toney, J. H., Murthy, S. M., and Marks, T. J. Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice. Chem.-Biol. Interact., 56: 45-54, 1985.
26. Vinklarek, J., Pavlik, I., and Cernosek, Z. Behaviour of the antitumor agent vanadocene dichloride in physiological and therapeutic media, blood plasma and human blood - an EPR study. Metal based drugs. 4: 207-219, 1997.
27. Ghosh, P., Kotchevor, A. T., DuMez, D. D., Ghosh, S., Peiterson, J., and Uckun, F. M. Synthesis and structure of bis(π-cyclopentadienyl)vanadium (IV) 1,10-phenanthroline and 2,2′-bipyridine compounds and their interactions with artificial membranes. Inorg. Chem., 38: 3730-3737, 1999.
28. Perrin, D. D., and Armereago, W. L. F. In: Purification of Laboratory Chemicals, Ed. 3. New York: Pergamon Press, 1988.
29. Wilkinson, G., and Birmingham, J. M. Bis-cyclopentadienyl compounds of Ti, Zr, V, Nb, and Ta. J. Am. Chem. Soc., 76: 4281-4284, 1954.
30. Cardin, D. J., Lappart, M. F., Raston, C. L., and Riley, P. I. In: Comprehensive Organometallic Chemistry, Vol. 3, pp. 554-646. New York: Pergamon Press, 1982.
31. Eisch, J. J., and King, R. B. Organometallic Synthesis, Vol. 1, pp. 75-76. New York: Academic Press, 1965.
32. Doyle, G., and Tobias, R. S. Pseudohalide and chelate complexes of bis(cyclopentadienyl)vanadium(IV). Inorg. Chem., 7: 2479-2484, 1968.
33. 2Y]. Eur. J. Med. Chem./Chim. Ther., 19: 347-352, 1984.
34. Neuse, E. W., and Meirim, M. G. A chlorotitanocene tetrachlorferrate complex stabilized by acetonitrile coordination. Transition Met. Chem., 9: 337-338, 1984.
35. -)2. J. Organometallic Chem., 302: 193-200, 1986.
36. Casey, A. T., and Thackeray, J. R. Dithiochelates of the bis(π-cyclopentadienyl)vanadium(IV) moiety. II. N,N-Dialkyldithiocarbamate and O,O′-dialkyldithiophosphate complexes. Aust. J. Chem., 27: 757-768, 1974.
37. D'Cruz, O. J., Ghosh, P., and Uckun, F. M. Spermicidal activity of chelated complexes of bis(cyclopentadienyl)vanadium(IV). Mol. Hum. Reprod., 4: 683-693, 1998.
38. Moran, M., Masaguer, J. R., and Fernandez, V. Synthesis and characterization of halogen and pseudohalogen derivatives of substituted vanadocenes. J. Organometallic Chem., 291: 311-319, 1985.
39. 2. Organometallics, 16: 1994-1996, 1997.
40. Narla, R. K., Liu, X., Myers, D. E., and Uckun, F. M. 4-(3′-Bromo-4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154): a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin. Cancer Res., 4: 1405-1414, 1998.
41. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
42. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
43. 2Ti or DNA-CpTi adducts depending on pH. J. Am. Chem. Soc., 112: 8949-8952, 1990.